Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer.

Brunetto E, De Monte L, Balzano G, Camisa B, Laino V, Riba M, Heltai S, Bianchi M, Bordignon C, Falconi M, Bondanza A, Doglioni C, Protti MP.

J Immunother Cancer. 2019 Feb 13;7(1):45. doi: 10.1186/s40425-019-0521-4.

2.

Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.

Di Lullo G, Marcatti M, Heltai S, Tresoldi C, Paganoni AM, Bordignon C, Ciceri F, Protti MP.

Front Immunol. 2019 Jan 21;9:3171. doi: 10.3389/fimmu.2018.03171. eCollection 2018.

3.

Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.

Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L, Marcatti M, Girlanda S, Tonon G, Ciceri F, Caligaris-Cappio F, Ferrarini M, Ferrero E.

Haematologica. 2018 Apr;103(4):707-716. doi: 10.3324/haematol.2017.167486. Epub 2018 Jan 11.

4.

Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients.

De Monte L, Wörmann S, Brunetto E, Heltai S, Magliacane G, Reni M, Paganoni AM, Recalde H, Mondino A, Falconi M, Aleotti F, Balzano G, Algül H, Doglioni C, Protti MP.

Cancer Res. 2016 Apr 1;76(7):1792-803. doi: 10.1158/0008-5472.CAN-15-1801-T. Epub 2016 Feb 12.

5.

Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.

Di Lullo G, Marcatti M, Heltai S, Brunetto E, Tresoldi C, Bondanza A, Bonini C, Ponzoni M, Tonon G, Ciceri F, Bordignon C, Protti MP.

Oncoimmunology. 2015 Feb 3;4(5):e1005460. eCollection 2015 May.

6.

Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms.

Moroni M, Ghezzi S, Baroli P, Heltai S, De Battista D, Pensieroso S, Cavarelli M, Dispinseri S, Vanni I, Pastori C, Zerbi P, Tosoni A, Vicenzi E, Nebuloni M, Wong K, Zhao H, McHugh S, Poli G, Lopalco L, Scarlatti G, Biassoni R, Mullins JI, Malnati MS, Alfano M.

J Transl Med. 2014 Dec 5;12:335. doi: 10.1186/s12967-014-0335-6.

7.

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

Malnati MS, Heltai S, Cosma A, Reitmeir P, Allgayer S, Glashoff RH, Liebrich W, Vardas E, Imami N, Westrop S, Nozza S, Tambussi G, Buttò S, Fanales-Belasio E, Ensoli B, Ensoli F, Tripiciano A, Fortis C, Lusso P, Poli G, Erfle V, Holmes H.

J Immunol Methods. 2012 Jan 31;375(1-2):46-56. doi: 10.1016/j.jim.2011.09.005. Epub 2011 Sep 22.

PMID:
21963950
8.

Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection.

Dembek CJ, Kutscher S, Heltai S, Allgayer S, Biswas P, Ghezzi S, Vicenzi E, Hoffmann D, Reitmeir P, Tambussi G, Bogner JR, Lusso P, Stellbrink HJ, Santagostino E, Vollbrecht T, Goebel FD, Protzer U, Draenert R, Tinelli M, Poli G, Erfle V, Malnati M, Cosma A.

AIDS Res Ther. 2010 Jul 2;7:20. doi: 10.1186/1742-6405-7-20.

9.

The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P, Nozza S, Tambussi G, Bogner JR, Stellbrink HJ, Goebel FD, Lusso P, Tinelli M, Poli G, Erfle V, Pohla H, Malnati M, Cosma A.

AIDS Res Ther. 2008 Oct 6;5:22. doi: 10.1186/1742-6405-5-22.

10.
11.

Evidence for the involvement of phosphatidylinositol 3-kinase in fMLP-stimulated neutrophil adhesion to ICAM-1-transfected cells.

Pellegatta F, Radaelli A, Heltai S, Yan L, Chierchia SL, Folli F.

J Cardiovasc Pharmacol. 2001 Jun;37(6):751-61.

PMID:
11392472
12.

Engagement of CD30 shapes the secretion of cytokines by human gamma delta T cells.

Biswas P, Rovere P, De Filippi C, Heltai S, Smith C, Dagna L, Poli G, Manfredi AA, Ferrarini M.

Eur J Immunol. 2000 Aug;30(8):2172-80.

13.

In vivo administration of GM-CSF promotes the clearance of apoptotic cells: effects on monocytes and polymorphonuclear leukocytes.

Galati G, Rovere P, Citterio G, Bondanza A, Scagliette U, Bucci E, Heltai S, Fascio U, Rugarli C, Manfredi AA.

J Leukoc Biol. 2000 Feb;67(2):174-82.

PMID:
10670577
14.

Generation of nitric oxide by the inducible nitric oxide synthase protects gamma delta T cells from Mycobacterium tuberculosis-induced apoptosis.

Sciorati C, Rovere P, Ferrarini M, Paolucci C, Heltai S, Vaiani R, Clementi E, Manfredi AA.

J Immunol. 1999 Aug 1;163(3):1570-6.

15.

Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines.

Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M.

J Immunol. 1999 Jul 1;163(1):130-6.

16.

Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes.

Ferrarini M, Imro MA, Sciorati C, Heltai S, Protti MP, Pellicciari C, Rovere P, Manfredi AA, Rugarli C.

Int J Cancer. 1999 May 17;81(4):573-9.

17.

Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets.

Wack A, Cossarizza A, Heltai S, Barbieri D, D'Addato S, Fransceschi C, Dellabona P, Casorati G.

Int Immunol. 1998 Sep;10(9):1281-8.

PMID:
9786427
18.

Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.

Imro MA, Dellabona P, Manici S, Heltai S, Consogno G, Bellone M, Rugarli C, Protti MP.

Hum Gene Ther. 1998 Jun 10;9(9):1335-44.

PMID:
9650618
19.

Mycobacterium tuberculosis exploits the CD95/CD95 ligand system of gammadelta T cells to cause apoptosis.

Manfredi AA, Heltai S, Rovere P, Sciorati C, Paolucci C, Galati G, Rugarli C, Vaiani R, Clementi E, Ferrarini M.

Eur J Immunol. 1998 Jun;28(6):1798-806.

20.

Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I.

Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, Balestrieri G, Sabbadini MG.

Arthritis Rheum. 1998 Feb;41(2):215-23.

PMID:
9485079
21.

Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies.

Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, Davoust J, Balestrieri G, Tincani A, Sabbadini MG.

Arthritis Rheum. 1998 Feb;41(2):205-14.

PMID:
9485078
22.

Autocrine nitric oxide modulates CD95-induced apoptosis in gammadelta T lymphocytes.

Sciorati C, Rovere P, Ferrarini M, Heltai S, Manfredi AA, Clementi E.

J Biol Chem. 1997 Sep 12;272(37):23211-5.

23.

Scavenger function of leukocytes phagocytosing apoptotic cells: analysis and quantitation by flow cytometry.

Galati G, Heltai S.

Eur J Histochem. 1997;41 Suppl 2:75-6. No abstract available.

PMID:
9859791
24.

Quantitative cytometry of MHC class I digestion from living cells.

Galati G, Arcelloni C, Paroni R, Heltai S, Rovere P, Rugarli C, Manfredi AA.

Cytometry. 1997 Jan 1;27(1):77-83.

25.

Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.

Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.

Eur J Immunol. 1996 Aug;26(8):1851-9.

PMID:
8765031
26.

Fas, apoptosis and the cell cycle.

Manfredi AA, Rovere P, Heltai S, Ferrarini M.

Immunol Today. 1996 Jul;17(7):345-6. No abstract available.

PMID:
8763824
27.

CD95 engagement releases calcium from intracellular stores of long term activated, apoptosis-prone gammadelta T cells.

Rovere P, Clementi E, Ferrarini M, Heltai S, Sciorati C, Sabbadini MG, Rugarli C, Manfredi AA.

J Immunol. 1996 Jun 15;156(12):4631-7.

PMID:
8648106
28.

Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.

Ferrarini M, Heltai S, Pupa SM, Mernard S, Zocchi R.

J Natl Cancer Inst. 1996 Apr 3;88(7):436-41.

PMID:
8618235
29.

Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro.

Protti MP, Imro MA, Manfredi AA, Consogno G, Heltai S, Arcelloni C, Bellone M, Dellabona P, Casorati G, Rugarli C.

Cancer Res. 1996 Mar 15;56(6):1210-3.

30.

Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.

Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G.

Eur J Immunol. 1995 May;25(5):1154-62.

PMID:
7539748
31.

Daudi lymphoma killing triggers the programmed death of cytotoxic V gamma 9/V delta 2 T lymphocytes.

Ferrarini M, Heltai S, Toninelli E, Sabbadini MG, Pellicciari C, Manfredi AA.

J Immunol. 1995 Apr 15;154(8):3704-12.

PMID:
7706713
32.

Constitutive expression of the heat shock protein 72 kDa in human melanoma cells.

Protti MP, Heltai S, Bellone M, Ferrarini M, Manfredi AA, Rugarli C.

Cancer Lett. 1994 Oct 14;85(2):211-6.

PMID:
7954339
33.

V delta 1+ gamma/delta T lymphocytes infiltrating human lung cancer express the CD8 alpha/alpha homodimer.

Ferrarini M, Heltai S, Chiesa G, Sabbadini MG.

Scand J Immunol. 1994 Sep;40(3):363-7.

PMID:
8091138
34.

Role of interleukin-2 in regulating lymphocyte activation and recirculation.

Fortis C, Ferrero E, Heltai S, Besana C, Corti C, Di Lucca G, Foppoli M, Consogno G, Rugarli C.

Eur J Cancer. 1993;29A(3):474-5. No abstract available. Erratum in: Eur J Cancer 1993;29A(7):1074.

PMID:
8398350
35.

Unusual expression and localization of heat-shock proteins in human tumor cells.

Ferrarini M, Heltai S, Zocchi MR, Rugarli C.

Int J Cancer. 1992 Jun 19;51(4):613-9.

PMID:
1601523
36.

Autoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: correlation with tumor regression.

Besana C, Sabbadini MG, Corti C, Di Lucca G, Foppoli M, Marcatti M, Heltai S, Rugarli C.

Tumori. 1991 Aug 31;77(4):339-42.

PMID:
1746057
37.

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.

Fortis C, Ferrero E, Biffi M, Heltai S, Besana C, Bucci E, Tresoldi M, Rugarli C.

Cancer Immunol Immunother. 1991;33(2):128-32.

PMID:
2036660
38.

Signal requirements for activation of leukaemic T cells from a chronic lymphocytic leukaemia (T-CLL).

Zocchi MR, Poggi A, Heltai S, Villa A, Inverardi L, Vicari A, Sabbadini MG, Ferrarini M.

Clin Exp Immunol. 1990 Oct;82(1):108-13.

39.

Evaluation of cytotoxic cell-target cell conjugates. Comparison between flow cytometric analysis and 51Cr binding assay.

Heltai S, Poggi A, Sabbadini MG, Zocchi MR.

Haematologica. 1990 Mar-Apr;75(2):191-3.

PMID:
2358208
40.

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.

Fortis C, Ferrero E, Besana C, Biffi M, Heltai S, Galli L, Borri A, Schoenheit A, Rugarli C.

Cancer Immunol Immunother. 1990;32(3):161-6.

PMID:
2289209
41.
42.

Cytologic and flow cytometric DNA analysis of multinucleated tumor cells and derived microcells.

Rampoldi E, Larizza L, Heltai S, Erba E, Ubezio P, Schirrmacher V.

Anal Quant Cytol Histol. 1989 Feb;11(1):59-66.

PMID:
2785808

Supplemental Content

Loading ...
Support Center